Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
A Phase Ib, Multi-center, Open-label Study of Z650 and Gemcitabine in Advanced Pancreatic Cancer
Sponsor: Sunshine Lake Pharma Co., Ltd.
Terminated
Combined with the analysis of the existing data of the trial, there was no obvious advantage compared with the clinical standard treatments, and the clinical trial was decided to be terminated based on the benefit of the subjects.
Other terminated trials from Sunshine Lake Pharma Co., Ltd.
- Hepatitis B, Chronic · Phase PHASE1/PHASE2 · Mar 2023
- Renal Cell Cancer Metastatic · Phase PHASE1/PHASE2 · May 2020
- Acute Myeloid Leukemia (AML) · Phase PHASE1 · Aug 2019
More terminations from Sunshine Lake Pharma Co., Ltd.
This PHASE1 trial investigates Pancreatic Cancer and is currently terminated or withdrawn. Sunshine Lake Pharma Co., Ltd. leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Apr 2021 — Jun 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Mar 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sunshine Lake Pharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .